Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CED of Nal-IRI in Children With DIPG
NCT03086616Phase 1Completed
- Start
- Oct 2017
- Primary completion
- Oct 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan liposome in diffuse intrinsic pontine glioma (DIPG). Primary endpoint: Number of Participants Experiencing Treatment-Related Adverse Events at 12 months. Started Oct 2017; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT03086616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086616.